DOPA decarboxylase
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | == | + | ==Your Heading Here (maybe something like 'Structure')==<StructureSection load='1dq8' size='500' side='right' caption='Pig DOPA decarboxylase complex with inhibitor carbidopa, vitamin B6 phosphate and sulfate, [[1js3]] ' scene=''> |
- | + | '''DOPA decarboxylase''' (DDC, aromatic L-amino acid decarboxylase, tryptophan decarboxylase, 5-hydroxytryptophan decarboxylase, AAAD) is an approximately 104 kDa protein that belongs to the '''aspartate aminotransferase family''' (fold type 1) of '''[http://en.wikipedia.org/wiki/Pyridoxal_phosphate ''PLP'']-dependent''' (vitamin B6-dependent) enzymes. The catalytically active form of the enzyme exists as a homodimer, typical of this class of enzymes.<ref name="schneider">PMID:10673430 </ref> The homodimeric form of the enzyme purified from [http://en.wikipedia.org/wiki/Sus_scrofa ''sus scrofa''] is shown in complex with the inhibitor '''[http://en.wikipedia.org/wiki/Carbidopa ''carbidopa'']''' to the right. [[image:dopa.png|thumb|left|500px|'''dopamine synthesis''']] | |
- | + | ||
- | + | ||
- | + | ||
- | ''' | + | |
DOPA decarboxylase is responsible for the synthesis of '''[http://en.wikipedia.org/wiki/Dopamine ''dopamine'']''' and [http://en.wikipedia.org/wiki/Serotoninn ''serotonin''] from '''[http://en.wikipedia.org/wiki/L-dopa ''L-DOPA'']''' and [http://en.wikipedia.org/wiki/L-5-Hydroxytryptophan ''L-5-hydroxytryptophan''], respectively. Due to its role in dopamine biosynthesis, DOPA decarboxylase has been implicated in '''[http://en.wikipedia.org/wiki/Parkinson%27s_disease ''Parkinson's disease'']''', a disease thought to be the result of the degeneration of dopamine-producing cells in the brain. In fact, decarboxylation of L-DOPA by DOPA decarboxylase is the controlling step for the formation of dopamine in patients with Parkinson's <ref name="hadjiiconstantinou">PMID:1904055 </ref> Currently, treatment for the disease is aimed at DOPA decarboxylase inhibition. Since dopamine cannot cross the blood-brain barrier, it cannot be used to directly treat Parkinson's disease. Thus, exogenously administered L-DOPA is the primary treatment for patients suffering from this neurodegenerative disease. Unfortunately, DOPA decarboxylase rapidly converts L-DOPA to dopamine in the blood stream, with only a small percentage reaching the brain. By inhibiting the enzyme, greater amounts of exogenously administered L-DOPA can reach the brain, where it can then be converted to dopamine. <ref name="burkhard">PMID:11685243 </ref> | DOPA decarboxylase is responsible for the synthesis of '''[http://en.wikipedia.org/wiki/Dopamine ''dopamine'']''' and [http://en.wikipedia.org/wiki/Serotoninn ''serotonin''] from '''[http://en.wikipedia.org/wiki/L-dopa ''L-DOPA'']''' and [http://en.wikipedia.org/wiki/L-5-Hydroxytryptophan ''L-5-hydroxytryptophan''], respectively. Due to its role in dopamine biosynthesis, DOPA decarboxylase has been implicated in '''[http://en.wikipedia.org/wiki/Parkinson%27s_disease ''Parkinson's disease'']''', a disease thought to be the result of the degeneration of dopamine-producing cells in the brain. In fact, decarboxylation of L-DOPA by DOPA decarboxylase is the controlling step for the formation of dopamine in patients with Parkinson's <ref name="hadjiiconstantinou">PMID:1904055 </ref> Currently, treatment for the disease is aimed at DOPA decarboxylase inhibition. Since dopamine cannot cross the blood-brain barrier, it cannot be used to directly treat Parkinson's disease. Thus, exogenously administered L-DOPA is the primary treatment for patients suffering from this neurodegenerative disease. Unfortunately, DOPA decarboxylase rapidly converts L-DOPA to dopamine in the blood stream, with only a small percentage reaching the brain. By inhibiting the enzyme, greater amounts of exogenously administered L-DOPA can reach the brain, where it can then be converted to dopamine. <ref name="burkhard">PMID:11685243 </ref> | ||
Line 77: | Line 73: | ||
#'''Architecture''': up-down bundle | #'''Architecture''': up-down bundle | ||
#'''Topology''': dopa decarboxylase | #'''Topology''': dopa decarboxylase | ||
+ | |||
+ | </StructureSection> | ||
==3D structures of DOPA decarboxylase== | ==3D structures of DOPA decarboxylase== |
Revision as of 01:29, 20 January 2012
==Your Heading Here (maybe something like 'Structure')==
|
3D structures of DOPA decarboxylase
Update November 2011
3k40 – DDC – Drosophila melanogaster
1js3 – pDDC + inhibitor – pig
1js6 - pDDC
3rbf, 3rbl – hDDC – human
3rch – hDDC + vitamin B6 phosphate + pyridoxal phosphate
References
- ↑ 1.0 1.1 Schneider G, Kack H, Lindqvist Y. The manifold of vitamin B6 dependent enzymes. Structure. 2000 Jan 15;8(1):R1-6. PMID:10673430
- ↑ Miles EW. The tryptophan synthase alpha 2 beta 2 complex. Cleavage of a flexible loop in the alpha subunit alters allosteric properties. J Biol Chem. 1991 Jun 15;266(17):10715-8. PMID:1904055
- ↑ Burkhard P, Dominici P, Borri-Voltattorni C, Jansonius JN, Malashkevich VN. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase. Nat Struct Biol. 2001 Nov;8(11):963-7. PMID:11685243 doi:http://dx.doi.org/10.1038/nsb1101-963
- ↑ Percudani R, Peracchi A. A genomic overview of pyridoxal-phosphate-dependent enzymes. EMBO Rep. 2003 Sep;4(9):850-4. PMID:12949584 doi:http://dx.doi.org/10.1038/sj.embor.embor914
- ↑ Aurora R, Rose GD. Helix capping. Protein Sci. 1998 Jan;7(1):21-38. PMID:9514257 doi:10.1002/pro.5560070103
- ↑ Jansonius JN. Structure, evolution and action of vitamin B6-dependent enzymes. Curr Opin Struct Biol. 1998 Dec;8(6):759-69. PMID:9914259
- ↑ 7.0 7.1 Ishii S, Mizuguchi H, Nishino J, Hayashi H, Kagamiyama H. Functionally important residues of aromatic L-amino acid decarboxylase probed by sequence alignment and site-directed mutagenesis. J Biochem. 1996 Aug;120(2):369-76. PMID:8889823
Proteopedia Page Contributors and Editors (what is this?)
Brittany Todd, Michal Harel, David Canner, Alexander Berchansky, Brian Hernandez